06.03.13
CPhI Worldwide, through a panel of the founding members, will release a series of monthly and annual reports assessing the changes taking place across the industry. The first monthly report on formulation and ingredients will be released mid-June. The goal of the panel is to utilize the members’ areas of expertise to analyze how the industry will change in five to 10 years in an annual report to be produced ahead of CPhI in October.
The panel has confirmed members including: Girish Malhorta (Epcot Int’l.) and Brian Carlin (FMC), experts on APIs and excipients, Ajaz Hussain (Wockhardt) and Ali Afnan (Step Change Pharma), who serve as regulatory and PAT experts, and Hedley Rees (PharmaFlow) and Bikash Chatterjee (Pharmatech Assoc.), who will share their knowledge of supply chain issues, quality systems, and the Asian market.
The CPhI short monthly reports include CPhI Pharma Insight Series, examining issues across drug delivery, formulation and ingredients, R&D, manufacturing, packaging and distribution, regulatory compliance, contract services and supply chain management, and QA/QC. The monthly reports will also feature raw data, which will be compiled from the wider industry via the CPhI Pharma Evolution site.
“Our vision was to harness the power of CPhI’s independent position within the industry so that we could produce an unbiased analysis of the global pharma sector and help bring different perspectives together. For the report’s content, we had to ensure we had the right mix of appropriate experts that could holistically examine the next five plus years’ worth of developments. The panel we realized was the crucial element in making the reports and platforms robust enough to offer advice that was globally relevant and practical in its implications,” said Andrew Pert, brand director of Pharma at CPhI.
The panel has confirmed members including: Girish Malhorta (Epcot Int’l.) and Brian Carlin (FMC), experts on APIs and excipients, Ajaz Hussain (Wockhardt) and Ali Afnan (Step Change Pharma), who serve as regulatory and PAT experts, and Hedley Rees (PharmaFlow) and Bikash Chatterjee (Pharmatech Assoc.), who will share their knowledge of supply chain issues, quality systems, and the Asian market.
The CPhI short monthly reports include CPhI Pharma Insight Series, examining issues across drug delivery, formulation and ingredients, R&D, manufacturing, packaging and distribution, regulatory compliance, contract services and supply chain management, and QA/QC. The monthly reports will also feature raw data, which will be compiled from the wider industry via the CPhI Pharma Evolution site.
“Our vision was to harness the power of CPhI’s independent position within the industry so that we could produce an unbiased analysis of the global pharma sector and help bring different perspectives together. For the report’s content, we had to ensure we had the right mix of appropriate experts that could holistically examine the next five plus years’ worth of developments. The panel we realized was the crucial element in making the reports and platforms robust enough to offer advice that was globally relevant and practical in its implications,” said Andrew Pert, brand director of Pharma at CPhI.